Home / CXCL10/IP-10/CRG-2 / Human CXCL10/IP-10/CRG-2 Antibody

Human CXCL10/IP-10/CRG-2 Antibody

Catalog #: AF-266-NA
29 Citations Datasheet
Catalog # Availability Size / Price Qty
AF-266-NA
AF-266-SP
CXCL10/IP-10 in Human PBMCs.
4 Images
Product Details
Citations (29)
FAQs
Supplemental Products
Reviews
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CXCL10/IP-10/CRG-2 Antibody Summary

Species Reactivity
Human
Specificity
Detects human CXCL10/IP-10/CRG-2 in direct ELISAs and Western blots.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
E. coli-derived recombinant human CXCL10/IP-10/CRG-2
Val22-Pro98
Accession # P02778
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.20 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
ELISA

This antibody functions as an ELISA detection antibody when paired with Mouse Anti-Human CXCL10/IP‑10/CRG‑2 Monoclonal Antibody (Catalog # MAB2661).

This product is intended for assay development on various assay platforms requiring antibody pairs. We recommend the Human CXCL10/IP-10 DuoSet ELISA Kit (Catalog # DY266) for convenient development of a sandwich ELISA or the Human CXCL10/IP-10 Quantikine ELISA Kit (Catalog # DIP100) for a complete optimized ELISA.

 
Immunohistochemistry
1-15 µg/mL
See below
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 
Immunocytochemistry
5-15 µg/mL
See below
Intracellular Staining by Flow Cytometry
2.5 µg/106 cells
Human peripheral blood monocytes treated with Recombinant Human IFN‑ gamma (Catalog # 285‑IF), fixed with paraformaldehyde, and permeabilized with saponin
Neutralization
Measured by its ability to neutralize CXCL10/IP‑10/CRG‑2-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR3. The Neutralization Dose (ND50) is typically 1-4 µg/mL in the presence of 0.2 µg/mL Recombinant Human CXCL10/IP‑10/CRG‑2.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunocytochemistry CXCL10/IP-10 antibody in Human PBMCs by Immunocytochemistry (ICC). View Larger

CXCL10/IP-10 in Human PBMCs. CXCL10/IP-10 was detected in immersion fixed PHA-treated human peripheral blood mononuclear cells (PBMCs) using 10 µg/mL Goat Anti-Human CXCL10/IP-10 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-266-NA) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

Immunohistochemistry CXCL10/IP-10/CRG-2 antibody in Human Tonsil by Immunohistochemistry (IHC-P). View Larger

CXCL10/IP‑10/CRG‑2 in Human Tonsil. CXCL10/IP-10/CRG-2 was detected in immersion fixed paraffin-embedded sections of human tonsil using Goat Anti-Human CXCL10/IP-10/CRG-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-266-NA) at 1 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Neutralization Chemotaxis Induced by CXCL10/IP‑10 and Neutralization by Human CXCL10/IP‑10 Antibody. View Larger

Chemotaxis Induced by CXCL10/IP‑10 and Neutralization by Human CXCL10/IP‑10 Antibody. Recombinant Human CXCL10/IP-10 (Catalog # 266-IP) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL10/IP-10 (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL10/IP-10 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-266-NA). The ND50 is typically 1-4 µg/mL.

ELISA Human CXCL10/IP-10/CRG-2 Antibody in ELISA Standard Curve. View Larger

Human CXCL10/IP‑10/CRG‑2 ELISA Standard Curve. Recombinant Human CXCL10/IP-10/CRG-2 protein was serially diluted 2-fold and captured by Mouse Anti-Human CXCL10/IP-10/CRG-2 Monoclonal Antibody (Catalog # MAB2661) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human CXCL10/IP-10/CRG-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-266-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL10/IP-10/CRG-2

CXCL10 was originally identified as an IFN-gamma -inducible gene in monocytes, fibroblasts, and endothelial cells. It has since been shown that CXCL10 mRNA is also induced by LPS, IL-1 beta, TNF-alpha, IL-12, and viruses. Additional cell types that have been shown to express CXCL10 include activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. CXCL10 is also expressed in psoriatic and lepromatous lesions of skin. The mouse homologue of human CXCL10, CRG-2, has been cloned and shown to share approximately 67% amino acid sequence identity with human CXCL10. Human CXCL10 cDNA encodes a 98 amino acid (aa) residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted protein. The amino acid sequence of CXCL10 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CXCL10 has been shown to be a chemoattractant for activated T-lymphocytes. CXCL10 has been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent antitumor effect. A chemokine receptor specific for CXCL10 and MIG has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.

References
  1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
  2. Wang, X. et al.(1996) J. Biol. Chem. 271:24286.
Entrez Gene IDs
3627 (Human); 15945 (Mouse)
Alternate Names
C7; chemokine (C-X-C motif) ligand 10; CRG2; CRG-2; CXCL10; gIP-10; IFI10; INP10; IP-10; mob-1; SCYB10

Product Datasheets

You must select a language.

x
Product Datasheet

Citations for Human CXCL10/IP-10/CRG-2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

29 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Epithelium-innate immune cell axis in mucosal responses to SIV
    Authors: Shang L, Duan L, Perkey KE et al.
    Mucosal Immunol
  2. The immunological characteristics of TSPAN1 expressing B cells in autoimmune hepatitis
    Authors: Yiyan Ou, Ruiling Chen, Qiwei Qian, Nana Cui, Qi Miao, Ruqi Tang et al.
    Frontiers in Immunology
  3. Gene expression profiling of primary human type I alveolar epithelial cells exposed to Bacillus anthracis spores reveals induction of neutrophil and monocyte chemokines
    Authors: JL Booth, ES Duggan, VI Patel, W Wu, DM Burian, DC Hutchings, VL White, KM Coggeshall, MG Dozmorov, JP Metcalf
    Microb. Pathog., 2018-04-25;0(0):.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Neutralization
  4. Human hepatocytes depletion in the presence of HIV-1 infection in dual reconstituted humanized mice
    Authors: RS Dagur, W Wang, Y Cheng, E Makarov, M Ganesan, H Suemizu, CL Gebhart, S Gorantla, N Osna, LY Poluektova
    Biol Open, 2018-02-13;0(0):.
    Applications: IHC-P
  5. Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?
    Authors: S Urra, MC Fischer, JR Martínez, L Véliz, P Orellana, A Solar, K Bohmwald, A Kalergis, C Riedel, AH Corvalán, JC Roa, R Fuentealba, CJ Cáceres, M López-Last, A León, N Droppelman, HE González
    Oncotarget, 2017-12-20;9(2):2445-2467.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  6. CXCL10 is upregulated in synovium and cartilage following articular fracture
    Authors: Bridgette D. Furman, Collin L. Kent, Janet L. Huebner, Virginia B. Kraus, Amy L. McNulty, Farshid Guilak et al.
    Journal of Orthopaedic Research
  7. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease
    Authors: Jillian M. Richmond, Dinesh S. Bangari, Kingsley I. Essien, Sharif D. Currimbhoy, Joanna R. Groom, Amit G. Pandya et al.
    Journal of Investigative Dermatology
  8. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
    Authors: Xinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, Donald Lawrence, David McDermott, Jun Zhou et al.
    Cancer Immunology Research
  9. CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata
    J Immunol, 2016-07-13;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  10. Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis
    Authors: M Liu, X Zeng, J Wang, Z Fu, J Wang, M Liu, D Ren, B Yu, L Zheng, X Hu, W Shi, J Xu
    Stem Cell Res Ther, 2016-04-23;7(1):63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  11. NK cell responses to simian immunodeficiency virus vaginal exposure in naive and vaccinated rhesus macaques.
    Authors: Shang L, Smith A, Duan L, Perkey K, Qu L, Wietgrefe S, Zupancic M, Southern P, Masek-Hammerman K, Reeves R, Johnson R, Haase A
    J Immunol, 2014-06-04;193(1):277-84.
    Species: Primate - Macaca mulatta (Rhesus Macaque)
    Sample Types: Whole Tissue
    Applications: IHC
  12. Neuroblastoma-derived TGF-beta1 modulates the chemokine receptor repertoire of human resting NK cells.
    Authors: Castriconi R, Dondero A, Bellora F, Moretta L, Castellano A, Locatelli F, Corrias M, Moretta A, Bottino C
    J Immunol, 2013-04-10;190(10):5321-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  13. Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation
    Authors: Ann E. Østvik, Atle V B Granlund, Marit Bugge, Nadra J. Nilsen, Sverre H. Torp, Helge L. Waldum et al.
    Inflammatory Bowel Diseases
  14. Expression and regulation of chemokines in murine and human type 1 diabetes.
    Authors: Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, Burrack A, Eberlein J, Hildemann SK, Homann D
    Diabetes, 2011-12-30;61(2):436-46.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  15. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor
    Authors: Taghi Manshouri, Zeev Estrov, Alfonso Quintás-Cardama, Jan Burger, Ying Zhang, Ana Livun et al.
    Cancer Research
  16. Expression and function of CXCL16 in a novel model of gout
    Authors: Jeffrey H. Ruth, Monica D. Arendt, M. Asif Amin, Salahuddin Ahmed, Hubert Marotte, Bradley J. Rabquer et al.
    Arthritis & Rheumatism
  17. CXCR3/Ligands Are Significantly Involved in the Tumorigenesis of Basal Cell Carcinomas
    Authors: Blanche Ka Ki Lo, Mei Yu, David Zloty, Bryce Cowan, Jerry Shapiro, Kevin John McElwee
    The American Journal of Pathology
  18. Regulation of lentivirus neurovirulence by lipopolysaccharide conditioning: suppression of CXCL10 in the brain by IL-10.
    Authors: Maingat F, Viappiani S, Zhu Y, Vivithanaporn P, Ellestad KK, Holden J, Silva C, Power C
    J. Immunol., 2009-12-30;184(3):1566-74.
    Species: Feline, Human
    Sample Types: Cell Lysates, Whole Tissue
    Applications: IHC-P, Western Blot
  19. Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema.
    Authors: Shan M, Cheng HF, Song LZ
    Sci Transl Med, 2009-10-28;1(4):4ra10.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: ICC, IHC-Fr
  20. Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease.
    Authors: Kim MJ, Romero R, Kim CJ, Tarca AL, Chhauy S, LaJeunesse C, Lee DC, Draghici S, Gotsch F, Kusanovic JP, Hassan SS, Kim JS
    J. Immunol., 2009-03-15;182(6):3919-27.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  21. Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells.
    Authors: Okumura S, Yuki K, Kobayashi R, Okamura S, Ohmori K, Saito H, Ra C, Okayama Y
    Clin. Immunol., 2008-10-19;130(2):175-85.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  22. Astrocytes produce interferon-alpha and CXCL10, but not IL-6 or CXCL8, in Aicardi-Goutières syndrome.
    Authors: van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW
    Glia, 2008-04-01;56(5):568-78.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  23. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.
    Authors: Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S
    Cancer Res., 2006-10-01;66(19):9509-18.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  24. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus.
    Authors: Meller S, Winterberg F, Gilliet M, Muller A, Lauceviciute I, Rieker J, Neumann NJ, Kubitza R, Gombert M, Bunemann E, Wiesner U, Franken-Kunkel P, Kanzler H, Dieu-Nosjean MC, Amara A, Ruzicka T, Lehmann P, Zlotnik A, Homey B
    Arthritis Rheum., 2005-05-01;52(5):1504-16.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  25. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10.
    Authors: van Marle G, Henry S, Todoruk T, Sullivan A, Silva C, Rourke SB, Holden J, McArthur JC, Gill MJ, Power C
    Virology, 2004-11-24;329(2):302-18.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: ICC, IHC-P
  26. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis.
    Authors: Ohshima K, Karube K, Kawano R, Tsuchiya T, Suefuji H, Yamaguchi T, Suzumiya J, Kikuchii M
    Int. J. Oncol., 2004-09-01;25(3):605-13.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  27. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS.
    Authors: Giunti D, Borsellino G, Benelli R, Marchese M, Capello E, Valle MT, Pedemonte E, Noonan D, Albini A, Bernardi G, Mancardi GL, Battistini L, Uccelli A
    J. Leukoc. Biol., 2003-05-01;73(5):584-90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  28. Imbalance in the expression of CXC chemokines correlates with bronchoalveolar lavage fluid angiogenic activity and procollagen levels in acute respiratory distress syndrome.
    Authors: Keane MP, Donnelly SC, Belperio JA, Goodman RB, Dy M, Burdick MD, Fishbein MC, Strieter RM
    J. Immunol., 2002-12-01;169(11):6515-21.
    Species: Human
    Sample Types: BALF, Whole Tissue
    Applications: ELISA Development, IHC-P
  29. Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees.
    Authors: Lauw FN, Dekkers PE, te Velde AA, Speelman P, Levi M, Kurimoto M, Hack CE, Van Deventer SJ, van der Poll T
    J. Infect. Dis., 1999-03-01;179(3):646-52.
    Species: Primate - Pan troglodytes (Chimpanzee)
    Sample Types: Plasma
    Applications: ELISA Development

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human CXCL10/IP-10/CRG-2 Antibody

There are currently no reviews for this product. Be the first to review Human CXCL10/IP-10/CRG-2 Antibody and earn rewards!

Have you used Human CXCL10/IP-10/CRG-2 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review